Summit Therapeutics Inc. (SMMT)
| Market Cap | 14.07B -18.9% |
| Revenue (ttm) | n/a |
| Net Income | -856.09M |
| EPS | -1.12 |
| Shares Out | 799.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,755,325 |
| Open | 17.36 |
| Previous Close | 17.17 |
| Day's Range | 16.82 - 17.62 |
| 52-Week Range | 12.07 - 29.23 |
| Beta | -1.52 |
| Analysts | Buy |
| Price Target | 29.70 (+68.85%) |
| Est. Earnings | Oct 23, 2026 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for SMMT stock is "Buy." The 12-month stock price target is $29.7, which is an increase of 68.85% from the latest price.
News
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Summit Therapeutics Proxy statement: Proxy filing
Summit Therapeutics filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
AstraZeneca completes $2B equity investment in Summit Therapeutics
Summit Therapeutics (SMMT) announced the successful closing of AstraZeneca’s (AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development o...
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment...
Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo
Summit Therapeutics (SMMT) announced a clinical trial collaboration agreement with Daiichi Sankyo (DSNKY) and AstraZeneca (AZN) to evaluate ivonescimab, a novel, potential first-in-class investigation...
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evalua...
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate...
Summit Therapeutics price target raised to $20 from $18 at Barclays
Barclays raised the firm’s price target on Summit Therapeutics (SMMT) to $20 from $18 and keeps an Equal Weight rating on the shares. The company’s equity deal with AstraZeneca could…
Morning Movers: Summit Therapeutics jumps after AstraZeneca investment
Sstock futures have edged higher in early trading as technology stocks stabilize, but elevated oil prices and Treasury yields tied to ongoing Middle East tensions continue to temper risk appetite.
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
Summit Therapeutics shares surged more than 20% in pre-market trading on Tuesday after AstraZeneca agreed to invest $2 billion in the company and collaborate on a series of clinical studies involving ...
Why Is Summit Therapeutics Stock (SMMT) Soaring in Premarket Today, Sept. 29?
Summit Therapeutics ($SMMT) stock is up 22% in Tuesday’s premarket trading. The gain came after AstraZeneca ($AZN) announced a $2 billion equity investment in Summit Therapeutics and a deal to…
AMD, Nvidia, Navitas, Summit Therapeutics, Fair Isaac, and More Stocks That Explain Today's Market
AMD was inching higher after announcing an $8.2 billion deal to buy World Labs, with other chip stocks gaining.
Summit Therapeutics price target raised to $43 from $40 at Citi
Citi raised the firm’s price target on Summit Therapeutics (SMMT) to $43 from $40 and keeps a Buy rating on the shares after the company announced a $2B investment from…
Closing Bell Movers: Summit Therapeutics jumps on AstraZeneca investment
Major indices started the week on a downswing as oil prices sprang higher after President Donald Trump rejected conditions for a ceasefire presented by Iran and Treasury yields extended their…
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
Summit shares surged in after-hours trading following the news of AstraZeneca's investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.
Summit Therapeutics up 15% after AstraZeneca makes $2B equity investment
In after-hours trading, shares of Summit Therapeutics (SMMT) are up 15% to $17.85.
Summit Therapeutics, AstraZeneca enter clinical collaboration agreement
Summit (SMMT) entered into a clinical collaboration agreement with AstraZeneca (AZN) to evaluate sonesitatug vedotin in combination with ivonescimab with the intent to start studies in certain gastroi...
AstraZeneca makes $2B equity investment in Summit Therapeutics
Summit Therapeutics (SMMT) announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifical...
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company's progress towards achieving its goal of making a significant difference in th...
Summit Therapeutics put volume heavy and directionally bearish
Bearish flow noted in Summit Therapeutics (SMMT) with 1,978 puts trading, or 1.3x expected. Most active are Oct-26 15 puts and Jan-27 20 calls, with total volume in those strikes…
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potent...
Summit Therapeutics reports updated OS results from Phase 3 Harmoni trial
Summit Therapeutics (SMMT) announced that updated overall survival results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific ant...
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential fir...
Summit partner announces updated data from Phase III HARMONi-2 trial
Summit Therapeutics (SMMT) noted that its partner Akeso announced that updated data, including overall survival, OS, from the randomized, double-blind Phase III HARMONi-2 trial featuring the investiga...